Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Multiple sclerosis relapse? 2,326 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 2,326 reports of Multiple sclerosis relapse have been filed in association with OCRELIZUMAB (OCREVUS). This represents 4.1% of all adverse event reports for OCRELIZUMAB.

2,326
Reports of Multiple sclerosis relapse with OCRELIZUMAB
4.1%
of all OCRELIZUMAB reports
7
Deaths
576
Hospitalizations

How Dangerous Is Multiple sclerosis relapse From OCRELIZUMAB?

Of the 2,326 reports, 7 (0.3%) resulted in death, 576 (24.8%) required hospitalization, and 18 (0.8%) were considered life-threatening.

Is Multiple sclerosis relapse Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 2,326 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Multiple sclerosis relapse?

DIMETHYL (6,852) FINGOLIMOD (6,728) NATALIZUMAB (6,478) INTERFERON BETA-1A (5,931) TERIFLUNOMIDE (4,745) GLATIRAMER (3,695) DALFAMPRIDINE (3,322) OFATUMUMAB (1,525) INTERFERON BETA-1B (1,229) PEGINTERFERON BETA-1A (945)

Which OCRELIZUMAB Alternatives Have Lower Multiple sclerosis relapse Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Multiple sclerosis relapse Reports All Drugs Causing Multiple sclerosis relapse OCRELIZUMAB Demographics